Skip to content
Live news Screener Coverage Pricing Docs REST API WebSocket API MCP server Company Use cases Blog Changelog Status Compare Contact
BIVI$1.24-0.04(-3.13%)From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television[10:30:00 AM ET]AMGN$439.26-8.02(-1.79%)IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER Amgen (NASDAQ:AMGN) today announced landmark interim Phase 3 results showing that IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's...[10:30:00 AM ET]JNJ$263.81-3.80(-1.42%)Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of...[8:54:00 AM ET]PBLS$24.79-2.13(-7.91%)Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors[8:45:00 AM ET]SMTC$131.80+6.68(+5.34%)Semtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026[8:00:00 AM ET]GMAB$43.85+3.85(+9.63%)Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer[7:00:00 AM ET]INCY$115.00-1.93(-1.65%)Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer[7:00:00 AM ET]NBTX$29.36+0.17(+0.58%)NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma[7:00:00 AM ET]ONC$377.63-4.64(-1.21%)BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026[4:15:00 AM ET]CMPX$0.77-0.03(-3.97%)Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026[4:15:00 AM ET]CELC$63.20-2.37(-3.61%)Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026[4:15:00 AM ET]ZYME$28.22-0.22(-0.77%)Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026[2:30:00 AM ET]

ARCC · NASDAQ

Ares Capital Corporation

$18.65 -0.15 (-0.80%)

Company overview

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also provides growth capital and general refinancing. The company prefers to invest in basic and growth manufacturing, business services, consumer products, healthcare products and services, and information technology service sectors, and also considers restaurants, retail, oil and gas, and technology sectors. It focuses on investments in the Northeast, Mid-Atlantic, Southeast, and Southwest regions from its New York office, the Midwest from Chicago, and the Western region from Los Angeles. The fund typically invests between $20 million and $200 million, with a maximum of $400 million, in companies with EBITDA between $10 million and $250 million.

Sector
Financial Services
Industry
Asset Management
Exchange
NASDAQ
Market cap
$13.4B
Employees
1,200
Headquarters
Los Angeles, CA
CEO
Kort Schnabel
Listed
October 5, 2004
P/E
11.44
Dividend yield
9.91%

Company financials

Revenue
$2.6B
Gross profit
$1.9B
Operating income
$1.7B
EBITDA
$2B
Net income
$1.2B
EPS
$1.63
Total assets
$30.7B
Total debt
$15.8B
Gross margin
70.82%
Net margin
43.69%
Earnings yield
8.74%

Price chart

17.6218.3018.9819.6520.33
ARCC 1D NASDAQ O18.72H18.73L18.56C18.64-0.15 (-0.80%)Vol1.70M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Source
Date
Type
Ticker Type Headline Source Published
ARCC Stock news Ares Capital: This 10%+ Yield Is An Undervalued Buy Seeking Alpha
ARCC Stock news The More They Drop, The More I Buy: 11%+ Yields With Massive Upside Seeking Alpha
ARCC Stock news How Much Passive Income $50,000 in Ares Capital, Main Street, Energy Transfer and ONEOK Could Generate 24/7 Wall Street
ARCC Stock news Is Most-Watched Stock Ares Capital Corporation (ARCC) Worth Betting on Now? Zacks Investment Research
ARCC Stock news Ares Capital (ARCC) Ascends While Market Falls: Some Facts to Note Zacks Investment Research
ARCC Stock news How Much Does a 62-Year-Old Need in a Roth IRA to Collect $6,100 a Month Tax-Free for Life? 247 Wallst
ARCC Stock news Stay Ahead of the Game With Ares Capital (ARCC) Q3 Earnings: Wall Street's Insights on Key Metrics Zacks Investment Research
ARCC Stock news 2 BDCs For Bargain Hunters Seeking Alpha
ARCC Stock news Top 5 Safe Dividend Stocks Paying 6.9%+ Right Now 24/7 Wall Street
ARCC Stock news Is It Worth Investing in Ares Capital (ARCC) Based on Wall Street's Bullish Views? Zacks Investment Research
ARCC Stock news 2 BDCs To Buy That Could Replace ARCC And OBDC In Your Portfolio Seeking Alpha
ARCC Stock news How a 73-Year-Old Collects $5,450 a Month From Just Three Tickers: SCHD, VICI, and ARCC 247 Wallst
ARCC Stock news Buy The Dip: Sustainable And Growing 10%+ Yields Seeking Alpha
ARCC Stock news Ares Capital (ARCC) Outperforms Broader Market: What You Need to Know Zacks Investment Research
ARCC Stock news The Roth IRA Setup That Pays $4,650 a Month and Sends Nothing to the IRS 247 Wallst
ARCC Stock news Boomers Are Quietly Buying These 7-9% ‘Forever Income' Dividend Stocks 24/7 Wall Street
ARCC Stock news The IRS Hates This: 2 High-Yield Stocks to Hide in Your Roth IRA Immediately 24/7 Wall Street
ARCC Stock news $8,550 a Month and Zero Bonds: The Dividend Portfolio Retirees Are Building Instead 247 Wallst
ARCC Stock news Ares Capital Corporation (ARCC) is Attracting Investor Attention: Here is What You Should Know Zacks Investment Research
ARCC Stock news Every Roth IRA Needs These High-Yield Dividend Stocks Over 6% 24/7 Wall Street
FAQ

Questions about Ares Capital Corporation

What does Ares Capital Corporation do?
Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also provides growth capital and general refinancing. The company prefers to invest in basic and growth manufacturing, business services, consumer products, healthcare products and services, and information technology service sectors, and also considers restaurants, retail, oil and gas, and technology sectors. It focuses on investments in the Northeast, Mid-Atlantic, Southeast, and Southwest regions from its New York office, the Midwest from Chicago, and the Western region from Los Angeles. The fund typically invests between $20 million and $200 million, with a maximum of $400 million, in companies with EBITDA between $10 million and $250 million.
What is ARCC's market cap?
Ares Capital Corporation (ARCC) is a listed stock with a live quote. The latest market cap on this page is $13.4B.
Where is Ares Capital Corporation headquartered?
Ares Capital Corporation is headquartered in Los Angeles, CA.
How do I get ARCC news from the API?
Call GET /v1/news?tickers=ARCC. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does ARCC news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ARCC, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the ARCC price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 2,000 REST requests a day. Paid Pro removes the daily cap. If you don't subscribe, the account stays on Free.